18 results on '"Franchino-Elder, Jessica"'
Search Results
2. Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program.
- Author
-
Firlik, Katrina S., Anupindi, Vamshi Ruthwik, Hayes, Vincent, DeKoven, Mitchell, Shaikh, Asif, and Franchino-Elder, Jessica
- Abstract
Objective: To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD). Methods: In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015–31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs. Results: Program participants (n = 262) demonstrated a 44% greater adherence during followup than nonparticipants (n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72–3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower (p = 0.08). Higher pharmacy costs partially offset lower healthcare costs. Conclusions: Program participants showed improved COPD medication adherence and persistence compared to nonparticipants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection
- Author
-
Wallace, Anna, Isenberg, Keith, York, Whitney, Shinde, Mayura, Barron, John, Franchino-Elder, Jessica, Sand, Michael, and Sidovar, Matthew
- Published
- 2020
- Full Text
- View/download PDF
4. Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study.
- Author
-
Clark, Brendan, Wells, Brian J, Saha, Amit K, Franchino-Elder, Jessica, Shaikh, Asif, Donato, Bonnie MK, and Ohar, Jill A
- Published
- 2022
- Full Text
- View/download PDF
5. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
- Author
-
Singer, David, Bengtson, Lindsay GS, Elliott, Caitlin, Buikema, Ami R, and Franchino-Elder, Jessica
- Published
- 2020
- Full Text
- View/download PDF
6. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
- Author
-
Gibson, Gary E., Luchsinger, José A., Cirio, Rosanna, Chen, Huanlian, Franchino-Elder, Jessica, Hirsch, Joseph A., Bettendorff, Lucien, Chen, Zhengming, Flowers, Sarah A., Gerber, Linda M., Grandville, Thomas, Schupf, Nicole, Xu, Hui, Stern, Yaakov, Habeck, Christian, Jordan, Barry, Fonzetti, Pasquale, Flowers, Sarah, and Gerber, Linda
- Subjects
ALZHEIMER'S disease ,ADVANCED glycation end-products ,AMNESTIC mild cognitive impairment ,POSITRON emission tomography ,CLINICAL trials ,BRAIN ,DISEASE progression ,ETHYLENE glycols ,AMINES ,TREATMENT effectiveness ,COMPARATIVE studies ,RANDOMIZED controlled trials ,RADIOPHARMACEUTICALS ,APOLIPOPROTEINS ,RESEARCH funding ,VITAMIN B1 ,DEOXY sugars ,STATISTICAL sampling - Abstract
Background: In preclinical models, benfotiamine efficiently ameliorates the clinical and biological pathologies that define Alzheimer's disease (AD) including impaired cognition, amyloid-β plaques, neurofibrillary tangles, diminished glucose metabolism, oxidative stress, increased advanced glycation end products (AGE), and inflammation.Objective: To collect preliminary data on feasibility, safety, and efficacy in individuals with amnestic mild cognitive impairment (aMCI) or mild dementia due to AD in a placebo-controlled trial of benfotiamine.Methods: A twelve-month treatment with benfotiamine tested whether clinical decline would be delayed in the benfotiamine group compared to the placebo group. The primary clinical outcome was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Secondary outcomes were the clinical dementia rating (CDR) score and fluorodeoxyglucose (FDG) uptake, measured with brain positron emission tomography (PET). Blood AGE were examined as an exploratory outcome.Results: Participants were treated with benfotiamine (34) or placebo (36). Benfotiamine treatment was safe. The increase in ADAS-Cog was 43% lower in the benfotiamine group than in the placebo group, indicating less cognitive decline, and this effect was nearly statistically significant (p = 0.125). Worsening in CDR was 77% lower (p = 0.034) in the benfotiamine group compared to the placebo group, and this effect was stronger in the APOEɛ4 non-carriers. Benfotiamine significantly reduced increases in AGE (p = 0.044), and this effect was stronger in the APOEɛ4 non-carriers. Exploratory analysis derivation of an FDG PET pattern score showed a treatment effect at one year (p = 0.002).Conclusion: Oral benfotiamine is safe and potentially efficacious in improving cognitive outcomes among persons with MCI and mild AD. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant.
- Author
-
Franchino‐Elder, Jessica, Gilligan, Adrienne, Song, Xue, Hartaigh, Briain O, Henriques, Caroline, Sainski‐Nguyen, Amy, and Wang, Cheng
- Subjects
- *
APIXABAN , *MEDICAL care costs , *ATRIAL fibrillation , *WARFARIN , *HOSPITAL emergency services , *PHARMACY - Abstract
Objective: To compare all‐cause healthcare costs among non‐valvular atrial fibrillation (NVAF) patients who switched from warfarin to novel oral anticoagulants (NOAC). Methods: Adult NVAF patients who switched from warfarin to dabigatran, rivaroxaban or apixaban were identified in MarketScan claims databases between 10/01/2010 and 12/31/2015. Patients were continuously enrolled for 12 months before the first NOAC claim and followed for 12 months or until medication switch, discontinuation, inpatient death or 12/31/2016. Dabigatran patients were matched 1 : 1 separately to rivaroxaban and apixaban. All‐cause costs were reported as per‐patient‐per‐month (PPPM) in 2017 US dollars. Key findings: A total of 8679 and 5761 dabigatran switchers were matched to rivaroxaban and apixaban switchers respectively (mean age 73–74 years; mean CCI 1.8–2.0). Compared with rivaroxaban, dabigatran switchers had significantly lower PPPM mean outpatient (OP) ($1265 versus $1587, P < 0.001), emergency department (ED, $67 versus $95, P < 0.001), OP office ($114 versus $119, P = 0.003), other OP services ($1085 versus $1373, P < 0.001) and OP pharmacy costs ($624 versus $660, P < 0.001). Compared with apixaban, dabigatran switchers had significantly lower mean PPPM ED ($67 versus $123, P < 0.001), OP office ($116 versus $121, P = 0.032), other OP services ($1062 versus $1434, P < 0.001), OP pharmacy ($633 versus $706, P < 0.001) and total healthcare costs ($3254 versus $3805, P = 0.016). Conclusions: Outpatient costs were considerably lower among dabigatran switchers compared with rivaroxaban. Total and OP healthcare costs were significantly lower for patients switching from warfarin to dabigatran versus apixaban. Use of dabigatran following warfarin discontinuation may enable healthcare cost savings among NVAF patients, as compared with rivaroxaban or apixaban. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
- Author
-
Chowdhury, Ritam, Franchino-Elder, Jessica, Wang, Li, Yuce, Huseyin, Wang, Cheng, and Hartaigh, Briain O.
- Published
- 2019
- Full Text
- View/download PDF
9. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
- Author
-
Gilligan, Adrienne M., Franchino-Elder, Jessica, Song, Xue, Wang, Cheng, Henriques, Caroline, Sainski-Nguyen, Amy, Wilson, Kathleen, Smith, David M., and Sander, Stephen
- Abstract
Background: This is one of the first head-to-head real-world evidence studies comparing stroke-related and bleed-related healthcare and resource utilization (HCRU) and costs among non-valvular atrial fibrillation (NVAF) patients initiating oral anticoagulants.Methods: Adult NVAF patients newly diagnosed and treated with dabigatran, rivaroxaban, or warfarin between 10/01/2010 and 12/31/2014 were identified using MarketScan Commercial and Medicare Supplemental databases. Per-patient-per-month stroke and bleed-related HCRU and costs were reported.Results: Dabigatran patients were matched 1:1 to 26,592 rivaroxaban and 33,024 warfarin patients (mean age=68 years). Compared to rivaroxaban, dabigatran patients had lower bleed-related inpatient and outpatient HCRU (0.004 vs. 0.005; 0.099 vs. 0.145) and significantly lower adjusted bleed-related costs ($116 vs. $172), all p <0.05. Compared to warfarin, dabigatran patients had significantly lower stroke-related outpatient visits (0.034 vs. 0.048, p<0.001) and higher bleed-related outpatient visits (0.101 vs. 0.091, p=0.045). Multivariate adjusted bleed-related costs were significantly lower for dabigatran patients than warfarin patients ($94 vs. $138, p<0.001).Conclusions: The results suggest that dabigatran patients had lower bleed-related HCRU and costs than rivaroxaban patients, and lower outpatient stroke-related HCRU, higher bleed-related outpatient HCRU, and lower bleed-related costs than warfarin patients. It provides valuable stroke-related and bleed-related HCRU and costs information among commercially insured and Medicare patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
10. HEALTH CARE RESOURCE UTILIZATION AND EXPENDITURES AMONG NEWLY DIAGNOSED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING ORAL ANTI-COAGULANTS: RESULTS FROM 100% MEDICARE 2010-2015 DATA
- Author
-
Chowdhury, Ritam, Franchino-Elder, Jessica, Wang, Li, Yuce, Huseyin, and Wang, Cheng
- Published
- 2019
- Full Text
- View/download PDF
11. F214. Health Care Resource Utilization is Higher in Patients Prior to Diagnosis With Schizophrenia Than Non-Schizophrenia Comparators in a Large Commercially Insured Population in the United States
- Author
-
Wallace, Anna, Isenberg, Keith, Barren, John, York, Whitney, Shinde, Mayura, Sidovar, Matt, Franchino-Elder, Jessica, and Sand, Michael
- Published
- 2018
- Full Text
- View/download PDF
12. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
- Author
-
Willey, Vincent, Franchino-Elder, Jessica, An-Chen Fu, Cheng Wang, Sander, Stephen, Hiangkiat Tan, Kraft, Elizabeth, and Jain, Rahul
- Abstract
Objectives With the approval of new non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation (NVAF), it is anticipated that their introduction may change NVAF treatment patterns; however, there is limited supporting real-world evidence. This study investigated guideline-recommended oral anticoagulation (OAC) treatment and persistence in newly diagnosed patients with NVAF to understand demographic and clinical characteristics. Design Retrospective observational administrative claims study in the USA. Setting Patients with NVAF with ≥1 pharmacy claim for OAC (warfarin, dabigatran, rivaroxaban or apixaban) and no atrial fibrillation diagnosis within 12 months prior to the first claim were identified in the HealthCore Integrated Research Database between 1 November 2010 and 30 November 2013. Participants 45 092 patients with NVAF were included. Outcomes The proportion of OAC-treated patients was stratified by CHADS
2 score. Treatment persistence was measured from OAC initiation to discontinuation, end of eligibility or end of study period (30 November 2014), whichever occurred first. Results Almost half of the patients (41.1%) received an OAC. The proportion treated differed slightly in baseline stroke risk (CHADS2 <2: 39.8%; CHADS2 =2 or 3: 42.4%; and CHADS2 >3: 40.3%: p<0.001). Treated patients were slightly younger (70±12.2 vs 71±14.3 years; p<0.001), more likely male (59.7% vs 52.5%; p<0.001) and had a slightly elevated stroke risk (CHADS2 : 2.03±1.3 vs 1.98±1.4; p<0.001) and a lower bleeding risk (HEMORR2 HAGES: 2.55±1.8 vs 2.80±1.9; p<0.001) relative to untreated patients. Overall, patients with higher CHADS2 scores had higher HEMORR2 HAGES scores. The mean follow-up was 2.25 years (2.25±0.85) and 72.7% of patients discontinued OACs; nearly 25% within 3 months and 55% within 12 months. The mean time to discontinuation was 255±249 days. Conclusions The proportion of patients with NVAF who received OAC treatment was lower than previously reported and differed slightly by stroke risk. Patients with an elevated stroke risk had a higher bleeding risk, suggesting that clinicians may incorporate both in the treatment decision. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
13. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
- Author
-
Gilligan, Adrienne M., Franchino-Elder, Jessica, Xue Song, Cheng Wang, Henriques, Caroline, Sainski-Nguyen, Amy, Wilson, Kathleen, Smith, David M., Sander, Stephen, Song, Xue, and Wang, Cheng
- Subjects
- *
ATRIAL fibrillation diagnosis , *ANTICOAGULANTS , *UTILIZATION review (Medical care) - Abstract
Objectives: Compare costs and healthcare resource utilization (HCRU) among newly-diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs apixaban, rivaroxaban, or warfarin.Methods: Newly-diagnosed adult NVAF patients initiating dabigatran, apixaban, rivaroxaban, or warfarin (index event) between October 1, 2010-December 31, 2014 were identified using MarketScan claims data, and followed until medication discontinuation, switch, inpatient death, enrollment end, or study end (December 31, 2015). Dabigatran patients were propensity-score matched 1:1 separately with apixaban, rivaroxaban, and warfarin patients. Per-patient-per-month (PPPM) all-cause cost, HCRU, and 30-day re-admissions were reported. Costs were analyzed using generalized linear models.Results: Final cohorts, each matched with dabigatran patients, included 8,857 apixaban patients, 26,592 rivaroxaban patients, and 33,046 warfarin patients. Dabigatran patients had lower adjusted PPPM total healthcare, inpatient, and outpatient costs compared to rivaroxaban ($4,093 vs $4,636, $1,476 vs $1,862, and $2,016 vs $2,121, respectively, all p ≤ .001) and warfarin ($4,199 vs $4,872, $1,505 vs $1,851, and $2,049 vs $2,514, respectively, all p < .001). Adjusted costs were similar for dabigatran and apixaban. Dabigatran patients had significantly fewer hospitalizations, outpatient visits, and pharmacy claims than rivaroxaban patients (0.06 vs 0.07, 4.84 vs 4.96 and 4.80 vs 4.93, respectively, all p < .020) and warfarin patients (0.06 vs 0.07, 4.77 vs 6.88, and 4.76 vs 5.89, respectively, all p < .001). Dabigatran patients had similar hospitalizations to apixaban, but higher outpatient visits (4.70 vs 4.31) and pharmacy claims (4.86 vs 4.61), both p < .001.Conclusions: This real-world study found adjusted all-cause costs were lower for dabigatran compared to rivaroxaban and warfarin patients and similar to apixaban patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. 4.47 Patient Characteristics and Patterns of Care Prior to Schizophrenia Diagnosis in a Large Commercially-Insured Population of Adolescents and Young Adults in the United States
- Author
-
Wallace, Anna, Barron, John, York, Whitney, Shinde, Mayura, Isenberg, Keith, Sidovar, Matthew, Franchino-Elder, Jessica, and Sand, Michael
- Published
- 2017
- Full Text
- View/download PDF
15. Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection.
- Author
-
Wallace, Anna, Isenberg, Keith, York, Whitney, Shinde, Mayura, Barron, John, Franchino-Elder, Jessica, Sand, Michael, and Sidovar, Matthew
- Abstract
Introduction: Many patients exhibit subsyndromal clinical findings of schizophrenia prior to diagnosis. Early treatment may mitigate schizophrenia development, yet little is known about comorbidities and healthcare resource utilization (HCRU) in these patients before diagnosis.Methods: This retrospective, longitudinal cohort study, conducted between January 1, 2007 and April 30, 2016, used claims data from the US HealthCore Integrated Research Database. Newly diagnosed patients with schizophrenia (International Classification of Diseases, Ninth Revision: 295.x or ICD 10 F20.%) were identified and matched (1:4) with non-schizophrenia comparators. Patients were 15-54 years of age with either ≥1 inpatient/emergency room claim with a primary schizophrenia diagnosis, or ≥2 claims in any setting with any schizophrenia diagnosis. Demographics, comorbidities, physician specialties, medications, and related services, and other HCRU were compared between cohorts for up to 5 years before diagnosis.Results: The schizophrenia cohort included 6732 patients (57.4% male, mean age 30.3 years for males and 36.2 years for females). All outcomes were more prevalent in the schizophrenia cohort than the comparator cohort. Substantial comorbidity, medication use, and HCRU were observed in the schizophrenia cohort even 4-5 years before diagnosis with increasing findings approaching diagnosis. From 4-5 years to 0-12 months before diagnosis, resource use increased from 20.5% to 53.3% for atypical antipsychotics, 29.3% to 48.2% for antidepressants, and 15.1% to 35.5% for psychiatric diagnostic examinations.Conclusions: Patients with schizophrenia extensively use healthcare resources up to 5 years before diagnosis. Our findings may help with developing predictive models to identify patients at high risk of schizophrenia. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Persistent Steroid Exposure Before Coronavirus Disease 2019 Diagnosis and Risk of Hospitalization in Patients With Chronic Obstructive Pulmonary Disease.
- Author
-
Myers LC, Murray RK, Donato BMK, Liu VX, Kipnis P, Shaikh A, and Franchino-Elder J
- Abstract
Background: It is unclear whether persistent inhaled steroid exposure in chronic obstructive pulmonary disease (COPD) patients before coronavirus disease 2019 (COVID-19) is associated with hospitalization risk., Objective: Our objective was to examine the association between persistent steroid exposure and COVID-19-related hospitalization risk in COPD patients., Study Design and Methods: This retrospective cohort study used electronic health records from the Kaiser Permanente Northern California health care system (February 2, 2020, to September 30, 2020) for patients aged ≥40 years with COPD and a positive polymerase chain reaction test result for COVID-19. Primary exposure was persistent oral and/or inhaled steroid exposure defined as ≥6 months of prescriptions filled in the year before the COVID-19 diagnosis. Multivariable logistic regression was performed for the primary outcome of COVID-19-related hospitalization or death/hospice referral. Steroid exposure in the month before a COVID-19 diagnosis was a covariate., Results: Of >4.3 million adults, 697 had COVID-19 and COPD, of whom 270 (38.7%) had COVID-19-related hospitalizations. Overall, 538 (77.2%) were neither exposed to steroids in the month before COVID-19 diagnosis nor persistently exposed; 53 (7.6%) were exposed in the month before but not persistently; 23 (3.3%) were exposed persistently but not in the month before; and 83 (11.9%) were exposed both persistently and in the month before. Adjusting for all confounders including steroid use in the month before, the odds ratio for hospitalization was 0.77 (95% confidence interval 0.41-1.46) for patients persistently exposed to steroids before a COVID-19 diagnosis., Interpretation: No association was observed between persistent steroid exposure and the risk of COVID-19-related hospitalization in COPD patients., (JCOPDF © 2022.)
- Published
- 2023
- Full Text
- View/download PDF
17. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
- Author
-
Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, and Franchino-Elder J
- Subjects
- Administration, Inhalation, Adrenergic beta-2 Receptor Agonists administration & dosage, Adult, Aged, Aged, 80 and over, Cohort Studies, Drug Combinations, Drug Therapy, Combination, Female, Follow-Up Studies, Glucocorticoids administration & dosage, Humans, Male, Medicare Part D economics, Middle Aged, Muscarinic Antagonists administration & dosage, Pulmonary Disease, Chronic Obstructive economics, Retrospective Studies, United States, Benzoxazines administration & dosage, Bronchodilator Agents administration & dosage, Pulmonary Disease, Chronic Obstructive drug therapy, Tiotropium Bromide administration & dosage
- Abstract
Background: The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists (LAMA + LABA) as preferred maintenance therapy for patients with symptomatic chronic obstructive lung disease (COPD) after monotherapy and stepping up to triple therapy (TT; LAMA + LABA + inhaled corticosteroids [ICS]) in case of further exacerbations. Restrictions on TT recommendations have primarily been driven by higher pneumonia risk associated with regular ICS use. Evidence suggests that TT is overprescribed, which may affect economic and clinical outcomes., Objective: To compare health plan-paid costs, COPD exacerbations, and pneumonia diagnoses among patients newly treated with a LAMA + LABA regimen composed of tiotropium (TIO) + olodaterol (OLO) in a fixed-dose combination inhaler (TIO + OLO) or TT in a U.S. Medicare Advantage Part D insured population., Methods: This retrospective study identified COPD patients aged ≥ 40 years who were initiating TIO + OLO or TT (index regimen) between January 1, 2014, and March 31, 2018, from a national administrative claims database. Continuous insurance coverage for 12 months pretreatment (baseline) and ≥ 30 days posttreatment (follow-up) was required. Patients were followed until the earliest of study end (May 31, 2018), discontinuation of index regimen (≥ 60-day gap in index regimen coverage), switch to a different regimen, or health plan disenrollment. Before analysis of outcomes, TIO + OLO and TT patients were 1:1 propensity score-matched on baseline demographics, comorbidities, COPD medication use, medical resource use, and costs. Cohort differences in post-match outcomes were assessed by Wald Z-test (annualized costs) and Kaplan-Meier method (time to first COPD exacerbation and pneumonia diagnosis)., Results: After matching, each cohort had 1,454 patients who were well balanced on baseline characteristics. Compared with TT, the TIO + OLO cohort incurred $7,041 (41.1%) lower mean COPD-related total costs ($10,094 vs. $17,135; P < 0.001); cohort differences in the medical component ($3,666 lower for TIO + OLO) were driven by lower mean acute inpatient costs ($3,053 lower for TIO + OLO). Combined mean COPD plus pneumonia-related medical costs were $5,212 (39.0%) lower for TIO + OLO versus TT ($8,209 vs. $13,421; P = 0.006), and total mean all-cause costs were $9,221 (30.4%) lower for TIO + OLO versus TT ($21,062 vs. $30,283; P < 0.001). Kaplan-Meier analysis found longer time to first severe COPD exacerbation ( P = 0.020) and first pneumonia diagnosis ( P = 0.002) for TIO + OLO versus TT and a lower percentage of TIO + OLO patients experiencing these events (severe COPD exacerbation: 9.0% vs. 16.1%; pneumonia: 14.5% vs. 19.3%). A secondary analysis, which expanded the TIO + OLO cohort to include any LAMA + LABA regimen, had similar findings for all outcomes., Conclusions: COPD patients initiating TIO + OLO incurred lower costs to health plans and experienced fewer COPD exacerbation and pneumonia events relative to TT. These findings provide important real-world economic and clinical insight into the GOLD recommendations for TIO + OLO and LAMA + LABA therapy. The study findings also indicate the continued inconsistency between the recommendations and real-world clinical practices pertaining to TT., Disclosures: This study was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Palli and Franchino-Elder are employees of BIPI. Frazer, DuCharme, Buikema, and Anderson are employees of Optum, which was contracted by BIPI to conduct this study. The authors received no direct compensation related to the development of the manuscript. BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.
- Published
- 2020
- Full Text
- View/download PDF
18. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
- Author
-
Wallace A, Barron J, York W, Isenberg K, Franchino-Elder J, Sidovar M, and Sand M
- Subjects
- Adolescent, Adult, Ambulatory Care economics, Ambulatory Care statistics & numerical data, Drug Costs, Female, Hospitalization economics, Hospitalization statistics & numerical data, Humans, Male, Middle Aged, Prescription Drugs economics, Retrospective Studies, Schizophrenia diagnosis, Schizophrenia therapy, Young Adult, Health Care Costs statistics & numerical data, Patient Acceptance of Health Care statistics & numerical data, Prescription Drugs therapeutic use, Schizophrenia economics
- Abstract
Background: The management of schizophrenia, a chronic, multifaceted mental health condition, is associated with considerable health care resource utilization (HCRU) and costs. Current evidence indicates that a high-risk and costly prodromal period, during which patients are likely symptomatic, precedes diagnosis. Better characterization and disease management during this stage could help to improve patient outcomes., Objective: To describe and compare HCRU and costs for up to 5 years before diagnosis in a cohort with schizophrenia versus a demographically matched cohort without schizophrenia in a commercially insured U.S., Methods: This retrospective study identified newly diagnosed schizophrenia patients using enrollee claims in the HealthCore Integrated Research Database between January 1, 2007, and April 30, 2016. The index date was defined as the date of the first medical claim with a schizophrenia diagnosis code. Schizophrenia patients were directly matched (1:4) by age, sex, and region to comparators without schizophrenia who were assigned the same index dates as their matched schizophrenia counterparts. Observation periods were 0-12, 13-24, 25-36, 37-48, and 49-60 months before the index date. Outcomes included HCRU and costs for inpatient admissions, emergency room visits, outpatient care (office visits and other outpatient services), and medications. Means, standard deviations, medians, and 95% confidence intervals were calculated for continuous variables; relative frequencies and percentages were calculated for categorical variables. Cohorts were compared with t-tests for continuous variables and chi-square tests for categorical variables. Differences across cohorts were estimated with individual generalized linear models for each observation period, controlling for gender, age, geographic region of residence, health plan type and subscriber status, behavioral pre-index comorbidities and chronic comorbidities during the period before diagnosis., Results: 6,732 schizophrenia patients were matched to 26,928 patients without schizophrenia. All-cause inpatient admissions were more prevalent among schizophrenia patients than their comparators for all time periods (49-60 months prediagnosis: 9% vs. 4%; 0-12 months prediagnosis: 33% vs. 4%). The schizophrenia cohort had higher adjusted all-cause per-patient per-month health care costs relative to comparators from the earliest period of 49-60 months prediagnosis ($557 [95% CI = 474-639] vs. $321 [95% CI = 288-355]) through 0-12 months prediagnosis ($1,058 [95% CI = 998-1,115] vs. $338 [95% CI = 320-355]). Behavioral health-related costs were different in each time period as were cost ratios (schizophrenia costs: comparator costs), which increased from 5.4 in the earliest period to 14.8 in the year before diagnosis., Conclusions: Schizophrenia patients had higher all-cause and behavioral health-related HCRU and costs before diagnosis than matched controls. Costs increased from 5 years to 1 year prediagnosis for schizophrenia patients driven primarily by inpatient hospital stays and prescription drug costs, but remained stable for comparators. Additional research is needed for the development of predictive models to aid in the identification of high-risk patients., Disclosures: This study was sponsored by Boehringer Ingelheim Pharmaceuticals. Barron is an employee of HealthCore, which received funding from Boehringer Ingelheim to conduct this study. Wallace and York were employed by HealthCore at time of this study. Isenberg is an employee of Anthem. Franchino-Elder, Sidovar, and Sand are employees of Boehringer Ingelheim.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.